The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Daratumumab plus Rd for newly diagnosed multiple myeloma (NDMM)
Thierry Facon, MD, of Lille University Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172). The trial looked at the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. lenalidomide/dexamethasone (Rd) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). Excitingly, the D-Rd regimen significantly reduced the risk of progression or death, with no new safety concerns. Dr Facon was speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
